Archive for the ‘Ligand Pharmaceuticals Inc.’ Category

Ligand Pharmaceuticals

February 26th, 2016 | Posted in 2016, Ligand Pharmaceuticals Inc.

Drugmaker Ligand Pharmaceuticals of San Diego has inked a licensing agreement with Tizona Therapeutics, San Francisco, to use three of Ligand’s animal platforms for producing human therapeutic antibodies (which can be used to develop drugs that boost the body’s immune response). Ligand’s animal platforms involve transgenic mice and rats that contain genetic material into which DNA from […]

Ligand Pharmaceuticals Inc.

December 22nd, 2015 | Posted in 2015, Ligand Pharmaceuticals Inc.

Ligand Pharmaceuticals Inc. has acquired Palo Alto-based Open Monoclonal Technology Inc. (OMT), a leader in genetic engineering of animals. The deal was for $178 million in cash and stock. The San Diego drugmaker focuses on developing programs that lead to licensing deals or acquiring royalty revenue-generating therapeutic assets. These therapies address a broad spectrum of diseases, including diabetes, […]

Ligand Pharmaceuticals

February 23rd, 2015 | Posted in 2015, Ligand Pharmaceuticals Inc.

Ligand Pharmaceuticals, San Diego, signed a license agreement with Sermonix Pharmaceuticals to develop and commercialize oral lasofoxifene. Lasofoxifene is an estrogen-partial agonist for the treatment of osteoporosis and other diseases. Ligand received an initial payment and is entitled to up to $5 million in potential regulatory and commercial milestone payments and tiered royalties.

Ligand Pharmaceuticals

September 22nd, 2014 | Posted in 2014, Ligand Pharmaceuticals Inc.

Ligand Pharmaceuticals, San Diego, expanded its global license agreement with CURx Pharmaceuticals to develop and commercialize Ligand’s Captisol-enabled Lamotrigine drug for hospital-base seizures. Ligand could receive up to $22 Million in milestone payments.

Ligand Pharmaceuticals

July 18th, 2014 | Posted in 2014, Ligand Pharmaceuticals Inc.

Ligand Pharmaceuticals announced a global licensing agreement for the development and commercialization of its Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) inhibitors. The agreement with TG Therapeutics will make Ligand eligible to receive tiered royalties of 6 – 9.5% on future net sales.

Ligand Pharmaceuticals Inc.

May 29th, 2014 | Posted in 2014, Ligand Pharmaceuticals Inc.

San Diego-based Ligand Pharmaceuticals has signed a research collaboration and licensing agreement with a wholly-owned subsidiary of AstraZeneca, Omthera Pharmaceuticals. Ligand will received payments of up to $44.5 million upon achieving certain milestones in the development of products to treat dyslipidemia, a high concentration of cholestorol, fat or other liquids in the blood.

Ligand Pharmaceuticals

April 17th, 2014 | Posted in 2014, Ligand Pharmaceuticals Inc.

Ligand Pharmaceuticals, Inc has earned a milestone payment of $200k from its Captisol licensee Lundbeck LLC. It was announced that the FDA has accepted a new drug application for review for its investigational therapy intravenous carbamazepine, an intravenous formulation of an anti-epileptic drug.

Ligand Pharmaceuticals Inc

June 22nd, 2011 | Posted in 2011, Ligand Pharmaceuticals Inc.

Ligand Pharmaceuticals Inc. – Announced that it has entered into a Captisol supply agreement with Merck & Company.  Ligand will supply clinical and commercial supplies of Captisol and, if the program is approved for commercialization, expects to deliver multiple tons of Captisol annually.

Ligand Pharmaceuticals Inc

April 13th, 2011 | Posted in 2011, Ligand Pharmaceuticals Inc.

Ligand Pharmaceuticals Inc. – La Jolla:  Is on track for its first profitable year, said Rob McKay the biotech’s Senior Director of Business Development. Ligand is a drug discovery and development company founded in 1987, and has endured annual net losses every year in large part due to an expensive overall cost structure, in addition […]